Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvation Bio Inc.NUVB · Entity 4384 | Chief Financial Officer | February 28, 2023 | March 02, 2023 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | May 28, 2026 | May 29, 2026 |
| Zenas BioPharma, Inc.ZBIO · Entity 275 | See Remarks | June 15, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvation Bio Inc.
Report date February 28, 2023 · Filed March 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.94 · Expires 2033-02-27 | Direct | 600,000 |
Reported balance
After 2023-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-28 · Grant · Acquired 600,000 · Balance 600,000 F2: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
| Class A Common StockSEC Table I · non-derivative | Direct | 4,481 |
Reported balance
Holding disclosure · report date 2023-02-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,481 F1: Includes 2,774 shares acquired on May 19, 2022 and 1 share acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,774 shares acquired on May 19, 2022 and 1 share acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
F2: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
PROKIDNEY CORP.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-05-28 | Direct | 135,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 135,000 · Balance 135,000 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Zenas BioPharma, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,592 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 1,592 · Balance 1,592 F1: Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026 in transactions that were exempt under Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.71 · Expires 2036-06-15 | Direct | 125,000 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 125,000 · Balance 125,000 F2: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026 in transactions that were exempt under Rule 16b-3(c).
F2: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apogee Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Disposition to issuer · Disposed 34,824 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.85 · Expires 2034-06-05 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Disposition to issuer · Disposed 10,370 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.66 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 14,461 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2036-06-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 7,657 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,657 | Not disclosed Strike: $85.00 | Not disclosed |
DisclosureSEC source: 0001140361-26-035612 · form4.xml · derivative · entry 4 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,657 shares Expires 2036-06-09 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,461 | Not disclosed Strike: $41.66 | Not disclosed |
DisclosureSEC source: 0001140361-26-035612 · form4.xml · derivative · entry 3 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,461 shares Expires 2035-06-17 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,370 | Not disclosed Strike: $43.85 | Not disclosed |
DisclosureSEC source: 0001140361-26-035612 · form4.xml · derivative · entry 2 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,370 shares Expires 2034-06-05 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerCommon Stock | 34,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-035612 · form4.xml · nonDerivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. F1 · price: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 22:00 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $18.71 | $0.00 |
DisclosureSEC source: 0001104659-26-075249 · tm2618042-1_4seq1.xml · derivative · entry 2 Fox Jennifer A. · CIK 0001841557 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-06-15 F2 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. Read SEC document |
| June 09, 2026 Filed Jun 12, 2026 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 7,657 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073058 · tm2617578-3_4seq1.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,657 Underlying: Common Stock · 7,657 shares Expires 2036-06-09 F1 · derivative.exercise_date: This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:06 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 135,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001193125-26-248256 · ownership.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Class A Common Stock · 135,000 shares Expires 2036-05-28 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| February 05, 2026 Filed Jun 17, 2026 22:00 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantCommon Stock | 1,592 | $13.35 | $21,253.20 |
DisclosureSEC source: 0001104659-26-075249 · tm2618042-1_4seq1.xml · nonDerivative · entry 1 Fox Jennifer A. · CIK 0001841557 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,592 F1 · balance_after: Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026 in transactions that were exempt under Rule 16b-3(c). Read SEC document |
| June 17, 2025 Filed Jun 21, 2025 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 14,461 | $0.00 Strike: $41.66 | $0.00 |
DisclosureSEC source: 0001104659-25-061273 · tm2518364-3_4seq1.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,461 Underlying: Common Stock · 14,461 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:38 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001104659-25-058943 · tm2517684-10_4seq1.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:13 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 125,862 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-25-080265 · ownership.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,862 Underlying: Class A Ordinary Shares · 125,862 shares Expires 2035-05-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:31 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 8,125 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001104659-24-129778 · tm2431489-2_4seq1.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,125 Underlying: Common Stock · 8,125 shares Expires 2034-12-15 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 00:48 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100326 · tm2424157-5_4seq1.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2034-09-11 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:03 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 9,535 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000950170-24-103630 · ownership.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,535 Underlying: Class A Ordinary Shares · 9,535 shares Expires 2034-09-03 F1 · derivative.exercise_date: The option shall vest and become exercisable on July 11, 2025 subject to Ms. Fox's continued service with the Company through the applicable vesting date. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 00:03 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 10,370 | $0.00 Strike: $43.85 | $0.00 |
DisclosureSEC source: 0001104659-24-069795 · tm2416491-3_4seq1.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,370 Underlying: Common Stock · 10,370 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:58 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 62,558 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000950170-24-068072 · ownership.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,558 Underlying: Class A Ordinary Shares · 62,558 shares Expires 2034-05-30 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 20:17 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 42,515 | $0.00 Strike: $10.92 | $0.00 |
DisclosureSEC source: 0001209191-23-042197 · doc4.xml · derivative · entry 2 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,515 Underlying: Class A Ordinary Shares · 42,515 shares Expires 2033-07-12 F2 · derivative.exercise_date: The option shall vest and become exercisable in two equal annual installments on July 11, 2024 and July 11, 2025 subject to Ms. Fox's continued service with the Company through the applicable vesting date. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 20:17 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 46,632 | $0.00 Strike: $10.92 | $0.00 |
DisclosureSEC source: 0001209191-23-042197 · doc4.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,632 Underlying: Class A Ordinary Shares · 46,632 shares Expires 2033-07-12 F1 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting subject to Ms. Fox's continued service with the Company through the applicable vesting date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:58 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001209191-23-014885 · doc4.xml · derivative · entry 2 Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Class A Common Stock · 600,000 shares Expires 2033-02-27 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:37 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantStock option (right to buy) · Derivative | 129,370 | $0.00 Strike: $9.73 | $0.00 |
DisclosureSEC source: 0001209191-22-051021 · doc4.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,370 Underlying: Class A ordinary share · 129,370 shares Expires 2032-09-20 F1 · derivative.exercise_date: The shares underlying the option award vest in three equal annual installments beginning on July 11, 2023, subject to Ms. Fox's continued service as a director of the Company. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 21:14 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 480,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001209191-22-048148 · doc4.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Class A Common Stock · 480,000 shares Expires 2032-08-28 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 19:32 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001209191-22-014585 · doc4.xml · derivative · entry 2 Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Class A Common Stock · 600,000 shares Expires 2032-02-27 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:46 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 558,506 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010330 · doc4.xml · derivative · entry 2 Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,506 Underlying: Class A Common Stock · 558,506 shares Expires 2030-10-11 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 558,506 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 20% on October 12, 2023, 20% on October 12, 2024 and 60% on October 12, 2025, subject to achievement of performance criteria. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:46 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010330 · doc4.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-11 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 25% on October 12, 2021 and in equal monthly installments thereafter over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.